Aeterna Zentaris Stock Price, News & Analysis (NASDAQ:AEZS) $2.08 +0.10 (+5.05%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.96▼$2.0850-Day Range$1.42▼$2.5052-Week Range$1.36▼$4.00Volume5,869 shsAverage Volume11,036 shsMarket Capitalization$10.11 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aeterna Zentaris MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside621.2% Upside$15.00 Price TargetShort InterestBearish0.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.22) to ($3.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector652nd out of 957 stocksPharmaceutical Preparations Industry311th out of 443 stocks 3.5 Analyst's Opinion Consensus RatingAeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Aeterna Zentaris has a forecasted upside of 621.2% from its current price of $2.08.Amount of Analyst CoverageAeterna Zentaris has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.98% of the float of Aeterna Zentaris has been sold short.Short Interest Ratio / Days to CoverAeterna Zentaris has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Aeterna Zentaris has recently increased by 1.50%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAeterna Zentaris does not currently pay a dividend.Dividend GrowthAeterna Zentaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEZS. Previous Next 3.9 News and Social Media Coverage News SentimentAeterna Zentaris has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week.Search Interest1 people have searched for AEZS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Aeterna Zentaris to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Aeterna Zentaris is held by insiders.Percentage Held by InstitutionsOnly 0.57% of the stock of Aeterna Zentaris is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aeterna Zentaris are expected to decrease in the coming year, from ($3.22) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeterna Zentaris is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeterna Zentaris is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeterna Zentaris has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aeterna Zentaris Stock (NASDAQ:AEZS)Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.Read More AEZS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEZS Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Now Covered by Analysts at StockNews.comNovember 14, 2023 | morningstar.comAEterna Zentaris Inc AEZSDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 9, 2023 | msn.comAeterna Zentaris GAAP EPS of -$0.85November 9, 2023 | finance.yahoo.comAeterna Zentaris Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | theglobeandmail.comAEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)October 30, 2023 | theglobeandmail.comAEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)October 11, 2023 | finance.yahoo.comAeterna Zentaris to Participate at the Virtual Investor Ask the CEO ConferenceDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. September 12, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Monday (AEZS)September 5, 2023 | finance.yahoo.comAeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 15, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)August 10, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)August 9, 2023 | finance.yahoo.comAeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue EstimatesJuly 13, 2023 | finance.yahoo.comAeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate UpdateJune 15, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Announces Results of Virtual 2023 Meeting of ShareholdersMay 26, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Friday (AEZS)May 17, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Tuesday (AEZS)May 15, 2023 | finance.yahoo.comAeterna Zentaris Announces Virtual 2023 Meeting of ShareholdersMay 12, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Aeterna Zentaris (AEZS)May 10, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comAeterna Zentaris Reports First Quarter 2023 Financial ResultsApril 27, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Wednesday (AEZS)April 6, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Thursday (AEZS)April 6, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Wednesday (AEZS)April 6, 2023 | finance.yahoo.comAeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone DrugApril 5, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Provides Update on Macrilen (Macimorelin), Reiterates Advancement of Pediatric DETECT TrialSee More Headlines Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AEZS CUSIPN/A CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees11Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+621.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,730,000.00 Net Margins-340.56% Pretax Margin-340.56% Return on Equity-49.10% Return on Assets-30.61% Debt Debt-to-Equity RatioN/A Current Ratio9.91 Quick Ratio9.89 Sales & Book Value Annual Sales$5.64 million Price / Sales1.79 Cash FlowN/A Price / Cash FlowN/A Book Value$5.41 per share Price / Book0.38Miscellaneous Outstanding Shares4,860,000Free Float4,851,000Market Cap$10.11 million OptionableOptionable Beta1.63 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Klaus Paulini Ph.D.President, CEO & Executive DirectorMr. Giuliano La FrattaSenior VP of Finance & CFODr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific OfficerDr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical DevelopmentDr. Matthias GerlachSenior Vice President Manufacturing & Supply ChainKey CompetitorsAraviveNASDAQ:ARAVKazia TherapeuticsNASDAQ:KZIAVaccinexNASDAQ:VCNXNeuroSense TherapeuticsNASDAQ:NRSNNightHawk BiosciencesNYSE:NHWKView All Competitors AEZS Stock Analysis - Frequently Asked Questions Should I buy or sell Aeterna Zentaris stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks. What is Aeterna Zentaris' stock price target for 2024? 1 analysts have issued twelve-month target prices for Aeterna Zentaris' stock. Their AEZS share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 621.2% from the stock's current price. View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts. How have AEZS shares performed in 2023? Aeterna Zentaris' stock was trading at $3.18 at the beginning of the year. Since then, AEZS stock has decreased by 34.6% and is now trading at $2.08. View the best growth stocks for 2023 here. When is Aeterna Zentaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AEZS earnings forecast. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.24. Aeterna Zentaris had a negative trailing twelve-month return on equity of 49.10% and a negative net margin of 340.56%. When did Aeterna Zentaris' stock split? Aeterna Zentaris's stock reverse split on the morning of Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG). Who are Aeterna Zentaris' major shareholders? Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AEZS) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.